22. The method according to claim 1 to 21, wherein the co-jet milling is carried out at an inlet pressure of between 3 and 12 bar, preferably at an inlet pressure of between 4 and 10 bar, or more preferably at an inlet pressure of between 5 and 9 bar.

23. The method according to claim 1 to 22, wherein the co-jet milling is carried out at a grinding pressure of more than 2 bar below the inlet pressure.

24. The method according to claim 23, wherein the grinding pressure is carried out at between 1 and 10 bar, preferably at a pressure of between 2 and 8 bar, or more preferably at a pressure of between 3 and 7 bar.

25. A method of making a dry powder formulation, the method comprising co-jet milling unmicronised glycopyrrolate and magnesium stearate with milling gas having a humidity below 20% Relative Humidity to produce micronized composite particles, wherein the micronized composite particles are then subjected to a conditioning step which includes exposure of the micronized composite particles to humidity in the range of 10%-95% RH at temperatures between 5°C to 88°C for at least 10 minutes.

26. A formulation comprising co-jet milled and then co-conditioned particles comprising glycopyrrolate and magnesium stearate obtained or obtainable by a method according to any preceding claim, optionally for use in a treatment of a respiratory disease, or for use in the preparation of a medicament for the treatment of a respiratory disease.

27. The formulation according to claim 26, wherein the formulation further comprises a beta-2 adrenoceptor agonist, preferably wherein the beta-2 adrenoceptor agonist is albuterol (salbutamol), metaproterenol, terbutaline, salmeterol, fenoterol, procaterol, preferably, formoterol, carmoterol and pharmaceutically acceptable salts thereof, more preferably wherein the beta-2 adrenoceptor agonist is (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]- 8-hydroxy-1H-quinolin-2-one maleate.

28. The formulation according to claim 26, wherein the formulation comprises glycopyrrolate, indacaterol and mometasone, preferably glycopyrronium bromide, indacaterol maleate and mometasone furoate.

29. A formulation according to claim any one of claims 26 to 28 or a method according to any one of claims 1 to 25 wherein the glycopyrrolate is a racemate.

30. A formulation according to any one of claims 26 to 29 or a method according to any one of claims 1 to 25 wherein the glycopyrrolate is a single enantiomer.

31. A formulation according to any one of claims 26 to 30 or a method according to any one of claims 1 to 25, wherein the magnesium stearate forms a coating on the surface of the glycopyrrolate particles as measured by energy-dispersive X-ray spectroscopy.

32. A formulation according to any one of claims 26 to 31 or a formulation obtained or obtainable by a method according to any one of claims 1 to 25 wherein the formulation is for use in treatment of a respiratory condition.

33. A formulation according to claims 26 to 32, further comprising carrier particles, wherein the span of the co-jet milled and co-conditioned glycopyrrolate and magnesium stearate particles is less than 150, more preferably less than 125, more preferably less than 100, or more preferably less than 50 prior to blending with the carrier particles.

34. A dry powder inhaler containing a formulation comprising co-jet milled and then co-conditioned particles comprising glycopyrrolate and magnesium stearate as claimed in any one of claims 26 to 33.

35. Use of co-jet milled and co-conditioned particles according to any claims 26-34 in the manufacture of a medicament for the treatment of a respiratory disease, preferably wherein the respiratory disease is chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF) and related airway diseases.

36. A pharmaceutical kit comprising micronized composite particles made by a method according to claims 1-24 and a further active according to claim 27, in combined or separate unit dosage forms, said forms being suitable for administration of the co-jet milled glycopyrrolate and the further active in effective amounts, optionally together with one or more inhalation devices for administration of both actives.